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ABSTRACT
Introduction: Full-thickness macular hole
(FTMH) formation is rarely seen in patients with
retinitis pigmentosa (RP) and can have an
adverse impact on their residual visual function.
The underlying mechanisms are unknown, and
clinical experience is limited regarding surgical
outcomes. Here, we describe the surgical man-
agement of FTMH in a young patient with
genetically confirmed Usher syndrome, the
most common form of syndromic RP.
Case Report: A 28-year-old woman presented
with blurred vision in her right eye (RE). She
had a history of RP and bilateral hearing
impairment since childhood. Fundoscopy and
spectral-domain optical coherence tomography
revealed a FTMH in the RE along with typical RP
features bilaterally. After pars plana vitrectomy
(PPV) with internal limiting membrane peel
and gas tamponade, the FTMH closed. Six
months after PPV the patient underwent catar-
act surgery in the affected eye, and the visual
acuity remained stable compared to baseline.
The clinical diagnosis of Usher syndrome was
genetically confirmed by whole exome
sequencing (WES), which revealed the presence
of two pathogenic nucleotide variants in trans
(compound heterozygosity) in the gene USH2A.
Conclusion: We report a rare case of successful
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syndrome. Surgical treatment of FTMH can help
preserve the central vision in RP patients, whose
peripheral vision is severely affected.
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plana vitrectomy; Retinitis pigmentosa; Usher
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Key Summary Points
Full-thickness macular hole (FTMH)
formation is rarely seen in patients with
retinitis pigmentosa (RP) and can have an
adverse impact on their residual visual
function, while clinical experience is
limited regarding surgical outcomes.
We report a rare case of successful closure
of a FTMH in a patient with Usher
syndrome, the most common form of
syndromic RP, which was genetically
confirmed.
This is the first case of FTMH in Usher
syndrome reporting surgical outcomes
combined with genetic data.
Vitrectomy appears to be effective in these
cases and should be performed to try to
preserve the central vision of RP patients
who usually have severely impaired
peripheral vision.
INTRODUCTION
Usher syndrome is an autosomal recessive dis-
order characterised by retinitis pigmentosa (RP),
sensorineural hearing loss and in some cases
vestibular dysfunction [1] with a prevalence
estimated to be between 6.2 and 16.67/100,000
[2, 3]. It is the most common form of syndromic
RP and accounts for about 10% of inherited
blindness caused by retinal dystrophies and
optic neuropathies [4]. Usher syndrome is
genetically heterogeneous and to date more
than ten genes have been identified as causative
of the disease [5, 6].
Although in RP the peripheral visual field is
typically constricted with initial sparing of the
central retina, macular abnormalities are often
observed, leading to reduction of the visual
acuity (VA). Cystoid macular oedema and
epiretinal membrane are the most common
macular anomalies in these patients, while the
presence of a macular hole is rare [7, 8]. Since in
RP patients the peripheral vision is affected, it is
important to detect and treat any potential
macular abnormalities to preserve central
vision. Due to the limited experience in cases of
macular hole in RP, it is useful to study the
outcomes and prognosis of surgical treatment.
Here, we report the anatomical and functional
outcomes of surgical management in a young
patient with Usher syndrome and full-thickness
macular hole (FTMH). The genetic pathogenic
variants underlying the patient’s condition are
also presented.
CASE PRESENTATION
A 28-year-old woman was referred to our
department with a complaint of blurred vision
during a period of 1 month in her right eye (RE).
She reported nyctalopia and restricted visual
field in both eyes since childhood and had been
diagnosed RP with no family history. She also
had had bilateral hearing impairment since
childhood and wore hearing aids.
At presentation, her best-corrected VA was
2.5/10 (- 1.00sph) in the RE and 3.5/10 (-
1.00cyl 9 90) in the left eye (Snellen). Anterior
segment examination was unremarkable with
bilateral clear lenses. Dilated fundoscopy
revealed a full-thickness macular hole and pos-
terior vitreous detachment in the RE. In addi-
tion, both eyes showed typical signs of RP
including peripheral retinal atrophy with bone
spicule-shaped pigmentation in the mid
periphery, waxy pallor of the optic nerve head
and attenuation of retinal vessels (Fig. 1). Spec-
tral domain optical coherence tomography (SD-
OCT) confirmed the presence of a FTMH stage
IV in the RE along with atrophy of the outer
retinal layers and absence of the ellipsoid zone
(Fig. 2a). In the fellow eye, thinning of the outer
retinal layers was also observed, while the
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ellipsoid zone was only preserved in the fovea
(Fig. 2b, d, f).
The patient underwent 23-gauge three-port
pars plana vitrectomy (PPV) with internal lim-
iting membrane (ILM) peeling assisted by
membrane dual blue and tamponade with 16%
hexafluoroethane (C2F6) gas. One month after
surgery, OCT (RE) confirmed the successful
closure of the macular hole with severe disrup-
tion of the ellipsoid zone (Fig. 2c). Due to pos-
terior subcapsular cataract development in the
RE, the patient subsequently underwent suc-
cessful uncomplicated cataract surgery with
phacoemulsification and intraocular lens
implantation 6 months after PPV. At final fol-
low-up, 11 months after PPV, the BCVA
remained stable at 2.5/10 (RE) while the macu-
lar hole remained closed and a small part of the
ellipsoid zone could be seen (Fig. 2e).
The scotopic full-field electroretinogram
(ffERG) was non-recordable in either of the eyes
indicating mostly loss of rod system sensitivity
(Fig. 3a, b). The responses obtained from the
photopic ERG, which entirely assesses cone
function, were reduced and delayed in both
eyes (Fig. 3c, d). These findings are in keeping
with rod-cone dystrophy [1]. Due to the co-ex-
istence of severe bilateral sensorineural hearing
impairment (data not shown), a clinical diag-
nosis of Usher syndrome was made.
After written informed consent had been
obtained from the patient and family members
Fig. 1 Pre-operative fundus photographs. a, b Fundus of
the right eye showing peripheral retinal atrophy with a few
intraretinal pigment deposits in a bone-spicule configura-
tion, retinal vessel attenuation and optic nerve head pallor,
while a full-thickness macular hole can be seen in the
macula. c, d The left eye also has a typical RP appearance
with multiple bone spicules in the periphery and a
relatively spared macula. RE right eye, LE left eye
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(approved by the Bioethics Committee of the
School of Medicine, Aristotle University of
Thessaloniki), saliva samples were obtained
from the patient and family members for sub-
sequent genomic DNA extraction (Oragene
DNA OG-500 saliva kits, DNA Genotek).
Genetic testing following whole exome
sequencing (WES) analyses revealed that the
patient carried two compound heterozygous
pathogenic variants in the USH2A gene (OMIM
608400, NM_007123.5) and in particular: a
nonsense mutation, c.100C[T, p.(Arg34Ter),
and a synonymous change c.949C[A,
p.(Arg317=), which has been shown to lead to a
new splice site [9]. The two variants, classified as
pathogenic in ClinVar by multiple submitters,
segregated with the phenotype in the patient’s
Fig. 2 SD-OCT of the macula of both eyes. a Pre-
operatively, in the right eye a FTMH (width 401 lm) and
a few intraretinal cystic spaces can be seen. There is also
thinning of the outer retinal layers and no ellipsoid zone
can be seen. b, d, f In the left eye, thinning of the outer
retinal layers is observed, while only the foveal part of the
ellipsoid zone is preserved. c One month after vitrectomy,
the FTMH is closed in the right eye. e Eleven months after
vitrectomy, the macular hole in the right eye remains
closed with only few photoreceptors remaining in the
temporal part of the fovea. RE right eye, LE left eye
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family (Fig. 4). Genetic counselling was given to
the patient and family members.
DISCUSSION
Macular abnormalities are relatively frequent in
RP patients, the most prevalent being cystoid
macular oedema, epiretinal membrane and vit-
reomacular traction [7, 8, 10]. FTMH in RP has
been reported to be rare (B 1%), although most
studies have focused on non-syndromic RP
patients [7, 10–12]. The only study including
exclusively Usher patients was performed by
Testa et al. [13] who demonstrated a high
prevalence of macular abnormalities (47%). In
this Italian cohort of 134 genetically confirmed
Usher cases, FTMH was found only in one eye of
a patient carrying USH2A mutations and thus
showing a prevalence of 0.4% [13].
The mechanism underlying the formation of
FTMH in RP remains unclear and is considered
multifactorial. Principally, abnormalities of the
vitreomacular interface, such as vitreomacular
traction and epiretinal membrane, are consid-
ered to be a major mechanism [11, 14, 15].
Moreover, atrophy due to chronic cystoid
macular oedema and macular schisis in highly
myopic eyes could potentially lead to FTMH
[12, 15]. Of note, our patient had posterior vit-
reous detachment in the affected eye, so our
hypothesis is that vitreomacular traction is the
underlying mechanism in this case.
Fig. 3 Full-field ERG findings indicating the presence of
rod-cone dystrophy. a, b Under scotopic conditions, the
ERG is non-detectable in both eyes. c, d Under photopic
conditions, the responses are reduced and delayed bilater-
ally. The x axis represents time in ms (20 ms/div). The
y axis represents potential in lV (a, b 50 lV/div, c-d
20 lV/div). DA dark-adapted, LA light-adapted, ERG
electroretinogram, RE right eye, LE left eye, N normal
Fig. 4 Genetic analysis of the patient’s family showing the
pedigree and segregation data for the pathogenic variants
in USH2A. The genotypes for all tested family members
are shown below each individual, with M1 representing the
first mutant allele, c.100C[T, p.(Arg34Ter), M2 the
second mutant allele, c.949C[A, p.(Arg317=) and ? rep-
resenting the wild-type allele. The affected individual is
shaded black
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The role of vitrectomy is established in the
treatment of idiopathic FTMH leading to a high
closure rate and significant VA improvement
compared to observation [16]. However, due to
the rarity of FTMH cases in the context of RP,
surgical outcomes have only been reported in a
few small case series including patients with
heterogeneous characteristics such as RP stage,
symptoms duration, baseline VA, FTMH size
and ocular comorbidities [10, 12, 14, 15, 17, 18].
Eight RP cases with FTMH have been reported to
have a successful anatomic outcome with seven
of them showing higher post-operative VA and
one of them having unaltered VA
[10, 14, 15, 18]. Another four cases with high
myopia have been reported, two of which were
accompanied by retinal detachment. All four
underwent vitrectomy resulting in successful
closure, with VA improvement in three
patients, while in the fourth one the VA dete-
riorated [12, 15, 18]. Moreover, in three patients
the FTMH failed to close after one vitrectomy
and resulted in worse VA [10, 14, 18]. Of note,
FTMH reopening after successful surgical inter-
vention has been reported in one patient [17].
Based on these studies, a successful closure of
the macular hole is achieved in the majority of
the cases, whereas the visual outcomes seem to
be mostly positive but can be variable. Thus, the
surgical treatment of these cases is usually
considered beneficial, notwithstanding the
potential risks of vitrectomy, including photo-
toxicity [19] and visual field defects [20]. The
presence of long-standing retinal degeneration
may affect the visual outcomes in RP patients.
In our patient the FTMH remained closed until
the most recent follow-up 11 months post-op-
eratively and the VA remained stable compared
to baseline.
Importantly, most of these studies have
included patients with either non-syndromic RP
or no clear clinical statement (syndromic vs.
non-syndromic RP) [10, 12, 15, 18]. The only
study reporting surgical outcomes of a FTMH
case with Usher syndrome was performed by
Vingolo et al. [21]. The authors report the
results from three cases including two RP
patients with lamellar holes and one Usher
subject with FTMH who underwent combined
microincision vitrectomy and cataract surgery.
The latter case was successful showing a VA
improvement from 2/20 to 4/20. However, the
underlying mechanism may be different from
our report because the macular holes were sec-
ondary to ‘‘chronic CMO and tangential vitre-
oretinal tractions’’. No OCT data were presented
for this patient [21].
No genetic data were presented in the
aforementioned reports of similar cases. To the
best of our knowledge, this is the first case of
surgical management of a FTMH in a patient
with genetically confirmed Usher syndrome. In
our patient, WES revealed two compound
heterozygous mutations in USH2A. Pathogenic
variants in this gene account for the majority
among the entire spectrum of genetic aberra-
tions present in patients with Usher syndrome
type 2 [4]. USH2A encodes usherin, localised to
the periciliary membrane complex, a region of
the photoreceptor inner segment that sur-
rounds the connecting cilium between the
outer and inner segment [22]. The stop muta-
tion, p.(Arg34Ter), has been previously reported
in several patients with Usher syndrome
[23, 24]. The second pathogenic variant,
p.(Arg317=), is predicted to activate a cryptic
donor splice site and has also been previously
reported [25, 26]. Its effect has been function-
ally assessed in vitro at the mRNA level
[r.(949C[A, 951_1143del)], where it was shown
to lead to the deletion of the last 193 bases of
exon 6 and thus result in the introduction of a
premature termination codon in exon 7 [9]. We
recommend that the genetic defects underlying
these patients’ RP should be reported, when
possible. Apart from the typical benefits of
genetic testing, such as obtaining an accurate
diagnosis, offering genetic counselling and
identifying patients eligible for gene therapy or
clinical trials, it could help us establish useful
genotype-phenotype correlations, e.g. while
examining whether specific genes or mutations
are associated with the development of macular
hole in RP.
CONCLUSION
We report a rare case of FTMH in a patient with
genetically confirmed Usher syndrome that was
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treated successfully with surgery. Our case
report supports the notion that vitrectomy is an
effective approach in these cases as demon-
strated by the successful anatomical outcome,
which stabilised central vision. Surgical man-
agement should therefore be selected to try to
preserve the central vision of these patients who
already may have severely impaired peripheral
vision. Further research is needed to enrich our
understanding and surgical experience in such
cases and potentially identify clinical and/or
genetic features related to the development and
prognosis of FTMH in the context of RP.
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